Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
    • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Russia Fosters Oncology Nursing Professional Development With ONS, EONS Presentations at Cancer Conference
    Oncology nursing community
    Russia Fosters Oncology Nursing Professional Development With ONS, EONS Presentations at Cancer Conference
    November 19, 2019
    Nurses Must Include Palliative Care Early for Their Patients
    Palliative care
    Nurses Must Include Palliative Care Early for Their Patients
    November 08, 2019
    Shared Structure Allows Nurses to Drive the Decision-Making Process
    Shared decision making (SDM)
    Shared Structure Allows Nurses to Drive the Decision-Making Process
    November 01, 2019
    What the First Patient I Ever Cared for Taught Me About Anxiety From New Beginnings
    Oncology nurse-patient relationship
    What the First Patient I Ever Cared for Taught Me About Anxiety From New Beginnings
    October 25, 2019
    Cancer Rehabilitation Serves a Critical Role in Patient Care
    Prehabilitation
    Cancer Rehabilitation Serves a Critical Role in Patient Care
    October 11, 2019
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
    • Home

    Author Content

    CDK4/6 Plus AI Is Effective for Older Women With Breast Cancer
    Breast cancer

    CDK4/6 Plus AI Is Effective for Older Women With Breast Cancer

    Combination treatment with a CDK4/6 inhibitor and aromatase inhibitor (AI) results in similar progression-free survival (PFS) rates in women with hormone receptor-positive, HER2-negative metastatic breast cancer who are aged 70 or older compared to younger women, according to study findings published in the Journal of Clinical Oncology.

    December 04, 2019
    Do Antibiotics Affect Response to Immune Checkpoint Inhibitors?
    Research

    Do Antibiotics Affect Response to Immune Checkpoint Inhibitors?

    Receiving antibiotics in the 30 days prior to starting immune checkpoint inhibitor treatment was associated with significantly reduced median overall survival, according to findings from a study published in JAMA Oncology. However, antibiotic use during treatment had no effect on survival.

    November 20, 2019
    Biomarker-Based Screening Test May Find Lung Cancer at Earlier Stages
    Lung Cancer

    Biomarker-Based Screening Test May Find Lung Cancer at Earlier Stages

    A blood test evaluating several biomarkers was able to reduce the number of lung cancers detected at later stages, according to study results presented at the 2019 World Conference on Lung Cancer.

    November 13, 2019
    How Oncology Nurses Can Support Patients During Financial Toxicity
    Patient financial advocacy

    How Oncology Nurses Can Support Patients During Financial Toxicity

    As groundbreaking yet high-cost cancer treatments make their way into clinical practice, the effects of financial toxicity can put a damper on the profound effects that new, lifesaving medications can have on patients with cancer. It’s a problem that even Washington, DC, hasn’t been able to address—so what can oncology nurses do about it?

    November 12, 2019
    USPSTF Updates Recommendations on Breast Cancer Prevention
    Research

    USPSTF Updates Recommendations on Breast Cancer Prevention

    Certain groups of women who are at increased risk for carrying BRCA1 or BRCA2 genes should be assessed for the need for genetic testing, and women at increased risk for breast cancer and low risk of adverse events should be offered risk-reducing medications, the U.S. Preventive Services Task Force (USPSTF) recommended.

    November 06, 2019
    New Liquid Biopsy Approach Is Accurate in Detecting Early Cancer
    Research

    New Liquid Biopsy Approach Is Accurate in Detecting Early Cancer

    A test that looks at circulating DNA rather than specific mutations is accurate in detecting 72% of early cancer cases and correctly identifying the tissue of origin in 75% of cases, researchers reported in study findings published in Nature.

    October 30, 2019
    Small Study Shows T-Cell Activity in Pancreatic Cancer
    Research

    Small Study Shows T-Cell Activity in Pancreatic Cancer

    When treated with their own nonengineered T cells plus chemotherapy, six of seven patients with inoperable or metastatic pancreatic cancer showed objective responses or stable disease, according to the results of a study reported at the American Association for Cancer Research’s Immune Cell Therapies for Cancer conference in July 2019.

    October 23, 2019
    Colorectal Cancer Diagnoses Increasing in Patients Younger Than 50
    Clinical practice

    Colorectal Cancer Diagnoses Increasing in Patients Younger Than 50

    Healthcare providers are seeing increasing numbers of younger patients with colorectal cancer, and they’re being diagnosed with more advanced stages of the disease, researchers reported in study findings published in the journal Cancer.

    October 16, 2019
    irAEs Linked to Improved Benefit From Pembrolizumab
    Immunotherapy

    irAEs Linked to Improved Benefit From Pembrolizumab

    Patients with advanced melanoma who received adjuvant therapy with pembrolizumab and subsequently developed immune-related adverse events (irAEs) saw a 63% reduced risk of recurrence, compared to 44% for those who did not develop irAEs. The study findings were presented at the 2019 American Society of Clinical Oncology annual meeting.

    October 09, 2019
    Patient Education Is Critical to Managing irAEs for Immune Checkpoint Inhibitors
    Immunotherapy

    Patient Education Is Critical to Managing irAEs for Immune Checkpoint Inhibitors

    By rebalancing the immune system and re-engaging mechanisms that tumor cells have shut off, immunotherapies such as immune checkpoint inhibitors enable patients’ own bodies to fight their cancers for them. But those same mechanisms can also result in immune-related adverse events (irAEs).

    October 08, 2019
    Pediatric Cancer Survivors Have Higher Mortality After Adult Breast Cancer Diagnosis
    Survivorship

    Pediatric Cancer Survivors Have Higher Mortality After Adult Breast Cancer Diagnosis

    Women who survived pediatric cancer but developed breast cancer as an adult are more than twice as likely to die prematurely, mostly from comorbid conditions, according to results of a study published in the Journal of Clinical Oncology.

    October 02, 2019
    Model May Help Predict Lung Cancer Risk in Patients With Nodules
    Cancer risk factors

    Model May Help Predict Lung Cancer Risk in Patients With Nodules

    A risk-prediction model that combines patients’ health history with clinical characteristics of their lung nodules may help physicians determine which will develop into cancer, according to the results of a study published in Cancer Prevention Research.

    September 25, 2019
    Vaccine May Boost CAR T-Cell Activity in Solid Tumors
    Research

    Vaccine May Boost CAR T-Cell Activity in Solid Tumors

    Researchers are testing a new approach using an amphiphilic cancer vaccine to deliver CAR T-cell therapy to solid tumors, and the results of preclinical studies are promising, according to findings published in the journal Science.

    September 18, 2019
    FDA Warns of Rare Lung Inflammation With Certain CDK 4/6 Inhibitors
    U.S. Food and Drug Administration (FDA)

    FDA Warns of Rare Lung Inflammation With Certain CDK 4/6 Inhibitors

    Palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) used to treat some patients with advanced breast cancers may cause rare but severe inflammation of the lungs, the U.S. Food and Drug Administration (FDA) announced on September 13, 2019. It approved new warnings about the risk on the prescribing information and package insert for the entire class of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor medicines. However, “the overall benefit of CDK 4/6 inhibitors is still greater than the risks when used as prescribed,” the agency noted.

    September 13, 2019
    Hematologic Cancers Have Higher Long-Term Risk of Clots and Bleeding
    Research

    Hematologic Cancers Have Higher Long-Term Risk of Clots and Bleeding

    Patients with hematologic cancers have a 19% increased risk for blood clots or bleeding events even 10 years after diagnosis, according to the results of a study published in the Journal of Thrombosis and Haemostasis.

    September 11, 2019
    Company Recalls TPN Bags Because of Leak and Infection Risk
    Safety

    Company Recalls TPN Bags Because of Leak and Infection Risk

    Bags used to store and administer total parenteral nutrition (TPN) are being recalled because of leaks near the divider rod and channel when the rod is removed, the Metrix Company of Dubuque, IA, announced on September 9, 2019.

    September 10, 2019
    Why Aren’t Nurses Adhering to PPE Requirements?
    Safety

    Why Aren’t Nurses Adhering to PPE Requirements?

    Oncology nurses are dedicated to providing the best, safest cancer care to their patients—protecting them from medical harm and prolonging life. But when it comes to protecting themselves, nurses sometimes take shortcuts in wearing personal protective equipment (PPE) that guards them against exposure to hazardous drugs. 

    September 10, 2019
    Oncology Formulations Not Affected by Bevacizumab Recall
    Prescription medication

    Oncology Formulations Not Affected by Bevacizumab Recall

    On September 3, 2019, AmEx Pharmacy issued a voluntary recall of two dosages of injectable bevacizumab. Although injectable bevacizumab is used in cancer treatment, the formulations affected by the recall are for much smaller dosages that are used to treat eye diseases (i.e., macular degeneration and diabetic retinopathy).

    September 06, 2019
    Melanoma Death Rates Are Falling Fast, Thanks to Immunotherapy
    Immunotherapy

    Melanoma Death Rates Are Falling Fast, Thanks to Immunotherapy

    Two-year survival rates for patients with advanced melanoma increased quickly after the introduction of ipilimumab in 2011, according to an analysis published the journal Cancer.

    September 04, 2019
    Hyperthyroidism Treatment Linked to Increased Cancer Death Risk
    Cancer risk factors

    Hyperthyroidism Treatment Linked to Increased Cancer Death Risk

    Radioactive iodine treatment for hyperthyroidism is associated with long-term risk of death from solid cancers, particularly breast cancer, according to the results of a study published in JAMA Internal Medicine. 
     

    August 21, 2019
    CAR T Cells Show Promise in Solid Tumors
    Research

    CAR T Cells Show Promise in Solid Tumors

    Two recent studies demonstrated CAR T-cell therapy activity in certain types of solid tumors, according to results presented at the American Society of Clinical Oncology annual meeting. The CAR T cells used new targets outside of the CD19 targets used for the therapy’s current approvals in leukemia and lymphoma. 
     

    August 14, 2019
    Immunotherapy Experts Identify Key Oncology Nursing Priorities at ONS Summit
    Immunotherapy

    Immunotherapy Experts Identify Key Oncology Nursing Priorities at ONS Summit

    Care coordination, appropriate adverse event assessment and treatment, and rapid, continuous learning are essential priorities for oncology nurses to care for patients receiving immunotherapy, according to the experts who participated in ONS’s immunotherapy summit in March 2018. 

    August 13, 2019
    Clinical Trial Participants Average 6.5 Years Younger Than Actual Cancer Populations
    Research

    Clinical Trial Participants Average 6.5 Years Younger Than Actual Cancer Populations

    For the four most common cancer sites (breast, prostate, colorectal, and lung cancer), the median age of patients in clinical trials is an average of 6.5 years younger than the median age of patients diagnosed with that cancer. And the age disparity is worsening, researchers reported in JAMA Oncology. 

    August 07, 2019
    Incidence of Aggressive Uterine Cancer Is Increasing
    Research

    Incidence of Aggressive Uterine Cancer Is Increasing

    U.S. incidence rates for aggressive uterine cancer subtypes are quickly rising for women aged 30-70, especially among non-Hispanic black women, according to results of a study published in the Journal of Clinical Oncology.

    July 24, 2019
    High Fitness Linked to Lower Risk and Mortality in Lung and Colorectal Cancers
    Research

    High Fitness Linked to Lower Risk and Mortality in Lung and Colorectal Cancers

    Adults with the highest cardiorespiratory fitness levels have a reduced risk for lung and colorectal cancer—and a lower risk of death if they do develop the cancers, according to findings from a study published in Cancer.

    July 17, 2019
    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9
    • …
    • Next page
    • Last page Last »
    picture of the author
    Elisa Becze BA, ELS, Editor
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap

  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
    • © Copyright 2019 Oncology Nursing Society
    Back to Top ▲